No experience
Employment Type:
Job Category:
Co-op: Internal Audit (1/2)
(This job is no longer available)
Biogen Idec | Cambridge, MA
Grad Date

Not sure what types of jobs you are interested in?

Explore Jobs
Based on Your Education

Follow This Company

Job Description

Job Description

The candidate will focus on assessing the operational effectiveness of financial controls (i.e., Sarbanes-Oxley 404 testing), but may also participate in other audit projects as needed. This work may include:

* Test the design and operating effectiveness of Sarbanes-Oxley control activities
* Execute testing of international affiliate financial controls and processes
* Execute Test Plans of remediation actions related to higher and moderate risk audit observations across a wide away of financial, operational and IT audit areas.
* Assist in the planning activities and execute test plans on various Financial, Operational and IT audits
* Prepare presentations for different levels of management

The candidate will function as an integral part of audit teams, working under the direction of the auditor-in-charge, to meet the objectives of audit activities within established deadlines.


To participate in the Biogen Co-op Program, students must meet the following eligibility criteria:

* Legal authorization to work in the U.S.
* Enrollment in a full-time undergraduate or graduate program, returning to the academic program following Intern/Co-op assignment
* Must be pursuing an undergraduate or post graduate degree in Accounting
* At least 18 years of age prior to the scheduled start date
* Completed at least one year of undergraduate studies

Additional qualifications:

* Excellent organization skills
* Excellent written and verbal communication skills
* Detail oriented
* Ability to multi-task and meet deadlines
* Self-motivated
* Ability to work in a team
* Strong computer skills including Microsoft Office suite


* Major: Accounting
* Minimum Overall GPA: 3.3
* Minimum Accounting GPA: 3.5
* Number of Accounting Credits: 15

About Biogen Idec

Biogen Idec Inc. is engaged in the development, manufacturing, and commercialization of therapies. The Company's products address diseases such as multiple sclerosis, lymphoma and rheumatoid arthritis. The Company has four products: AVONEX (interferon beta-1a), RITUXAN (rituximab), TYSABRI (natalizumab) and FUMADERM (dimethylfumarate and monoethylfumarate salts). AVONEX is used in the treatment of relapsing forms of multiple sclerosis (MS). RITUXAN is used in the treatment of relapsed or refractory low-grade or follicular, CD20-positive, and B-cell, non-Hodgkin's lymphomas (B-cell NHLs). TYSABRI is approved for the treatment of relapsing forms of MS. FUMADERM acts as an immunomudulator. It also has product candidates, such as BG-12 (acquired with the purchase of Fumapharm), ANTI-CD80 antibody/(galiximab), ANTI-CD23 antibody/(lumiliximab), Ocrelizumab/(Humanized ANTI-CD20 Antibody) and Lixivaptan.In January 2007, the Company completed the acquisition of Syntonix Pharmaceuticals, Inc. (Source: 10-K)